-

10:23:20 AM

IMMP Stock News

IMMP - Immutep Limited

06/07/23 8:00 AM

Nasdaq : IMMP

conferences

Immutep to Participate at the Jefferies Healthcare Conference

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces Marc Voigt, CEO of Immutep, will be

RHEA-AI

neutral

06/05/23 8:00 AM

Nasdaq : IMMP

Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meeting

Media Release Efti plus pembrolizumab led to deep, durable responses, regardless of PD-L1 expression levels, and median Duration of Response not reached despite median follow up of 39 months in TACTI-002 Phase II Promising efficacy in patients with a PD-L1 Combined Positive Score (CPS) of ≥1 with

RHEA-AI

neutral

06/02/23 8:00 AM

Nasdaq : IMMP

Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer

Immutep Limited, an Australian company (ASX: IMM) (Nasdaq: IMMP) ( Immutep or the Company), is pleased to announce the successful completion of an institutional placement ( Placement) and the institutional component ( Institutional Entitlement

RHEA-AI

neutral

05/29/23 8:00 AM

Nasdaq : IMMP

Immutep Selects Charles River Laboratories for IMP761’s GLP Toxicology Study

Media Release Appointment of Charles River Laboratories ("Charles River") to run Immutep’s preclinical toxicology study evaluating the safety and toxicity of IMP761 Forms a key step prior to first-in-human trials for this first-in-class LAG-3 agonist antibody designed to treat the underlying cause

RHEA-AI

very positive

05/26/23 8:00 AM

Nasdaq : IMMP

Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting

Media Release New data published from Part C of TACTI-002 Phase II Trial evaluating eftilagimod alpha plus pembrolizumab in metastatic 2nd line head and neck squamous cell carcinoma Deep, durable responses seen across all PD-L1 subgroups with a 13.5% Complete Response rate and median Duration of

RHEA-AI

very positive

05/25/23 8:00 AM

Nasdaq : IMMP

clinical trial

Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the first patient has been

RHEA-AI

very positive

05/24/23 8:00 AM

Nasdaq : IMMP

clinical trial

Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial

Media Release Efti plus standard-of-care anti-PD-1 therapy and doublet chemotherapy in 1st line non-small cell lung cancer is well tolerated and continues to show promising initial signals of efficacy Triple combination therapy has achieved a 67% response rate and 91% disease control rate in

RHEA-AI

positive

05/17/23 8:00 AM

Nasdaq : IMMP

Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer

Media Release Immuno-oncology combination of eftilagimod alpha (efti) and the leading anti-PD-1 therapy generates meaningful long-term survival in non-small cell lung cancer patients in Phase II TACTI-002 trial Initial median Overall Survival of 25 months in non-small cell lung cancer patients with

RHEA-AI

very positive

05/16/23 8:00 AM

Nasdaq : IMMP

clinical trial

Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received positive

RHEA-AI

positive

05/09/23 8:00 AM

Nasdaq : IMMP

conferences

Immutep to Participate in the JMP Securities Life Sciences Conference

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces its management will present and

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next